NCT03184467已完成2 期
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients
GemVax & Kael1 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2017年9月5日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- SIB (Severe Impairment Battery)
研究概览
简要总结
This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.
An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.
详细描述
GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
- Control group (placebo): 30 subjects
- Study group 1 (GV1001 0.56 mg): 30 subjects
- Study group 2 (GV1001 1.12 mg): 30 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •55 to 85 years of age
- •A patient who satisfies diagnostic criteria for dementia in DSM-IV
- •Probable Alzheimer's disease in NINCDS-ADRDA
- •K-MMSE ≤ 19 at screening and randomization visit
- •GDS 5~6 stage
- •MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's disease without any other disease that may cause dementia
- •A patient taking stable doses of donepezil for more than 3 months before screening visit
- •A patient who are able to visit a hospital (including inpatient and outpatient based) and receive cognitive and other tests
- •A patient with a caregiver who can accompany all visits and supervise the subject's compliance with the procedures and study drug prescribed in the protocol, and provide detailed information about the patient
- •Written informed consent by a patient or legal representative
排除标准
- •Any other cause of dementia shown by CT / MRI findings and neurological examination within 12 months of screening visit
- •Possible, probable or definite vascular dementia according to the NINDS-AIREN
- •Other central nervous system diseases that may cause cognitive impairment (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)
- •Neurological deficits such as delusions, delirium, epilepsy
- •Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results are thought to contribute to the severity of dementia or cause dementia
- •A patient who are considered ineligible for this study by investigator due to concurrent or history of significant psychiatric conditions (eg. schizophrenia or bipolar affective disorder)
- •A patient with a history of known or suspected seizures including febrile seizures, a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained
- •A patient with acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of clinical trials
- •Hypersensitivity to investigational medicinal products
- •History of alcohol, substance abuse or dependence (except nicotine dependence) within the last 2 years
- •Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer
- •Renal impairment (creatinine clearance (CLcr) <30 mL / min)
- •Severe liver dysfunction (ALT or AST> 2 times the upper limit of normal)
- •A patient taking other drugs other than donepezil to treat Alzheimer's disease or other cognitive impairment
- •A patient taking other drugs other than anticholinergic drugs, cholinergic drugs (local usages are allowable, such as pilocarpine eye drops), antidepressants (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat Alzheimer's disease
- •Women at childbearing age who do not consent using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study
- •Pregnancy or breast feeding
- •A patient who participated in other clinical trials within 4 weeks prior to this study
- •35 kg weight or below
- •A patient who had experienced this study drug
- •A patient who had participated in a clinical trial for Alzheimer dementia vaccine within last 6 months
- •Any other patients who are considered to be ineligible for this study by an investigator
研究组 & 干预措施
Control group
Placebo Comparator
Normal saline 0.9%
干预措施: Normal Saline 0.9% (Drug)
Study group 1
Experimental
GV1001 0.56 mg
干预措施: GV1001 0.56 mg (Drug)
Study group 2
Experimental
GV1001 1.12 mg
干预措施: GV1001 1.12 mg (Drug)
结局指标
主要结局
SIB (Severe Impairment Battery)
时间窗: week 24
Change in SIB compared to the baseline and week 24
次要结局
- K-MMSE (Korean-Mini-Mental State Examination)(week 24)
- CDR-SOB (Clinical Dementia Rating-Sum of Box)(week 24)
- ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe)(week 24)
- NPI (Neuropsychiatric Inventory)(week 24)
- GDS (Global Deterioration Scale)(week 24)
- CIBIC-plus (Clinician Interview-Based Impression of Change-Plus)(week 24)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase InjectionHemoptysisNCT03270735Lee's Pharmaceutical Limited100
Unknown
2 期
A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19Covid19NCT04627584Mabwell (Shanghai) Bioscience Co., Ltd.150
已完成
2 期
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)MelanomaNCT01009177Actelion80
Unknown
4 期
Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).Ankylosing SpondylitisNCT04934059China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.60
尚未招募
2 期
Study of the KPCXM18 Injection for Treatment of Acute Ischemic StrokeAcute Ischemic StrokeNCT05745311Kunming Pharmaceuticals, Inc.240